Nuveen’s BridgeBio Pharma BBIO Stock Holding History

Nuveen’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,155	Closed	-$20	–	3215
2023 Q2	$20	Buy	+1,155	New	+$17.4K	﹤0.01%	3198

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Nuveen's BBIO Position: Q2 2026 in Review

Nuveen increased its BridgeBio Pharma (BBIO) stake by 1.8% in Q2 2026, buying an estimated $707K and bringing the position to 572,789 shares worth $42.7M. The position accounts for 0.01% of the portfolio, ranked #803.

Nuveen first reported a position in BBIO in Q3 2019 and has held it in 28 quarters since. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Nuveen held 572,789 shares of BridgeBio Pharma worth $42.7M as of Q2 2026.
Nuveen bought 10,093 BridgeBio Pharma shares in Q2 2026, an estimated $707K.
BridgeBio Pharma made up 0.01% of Nuveen's portfolio in Q2 2026, its #803 holding.
Nuveen first reported a position in BridgeBio Pharma in Q3 2019 and has held it in 28 quarters since.
475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.